Report: the global ovarian cancer treatment market will reach 6.7 billion US dollars in 2028!

October 29, 2019 / bioun / -- global data, a global well-known market research company, released the latest research forecast that the global ovarian cancer market will have a market value of US $1.8 billion in 2018, and the market is expected to reach US $6.7 billion in 2028, with a CAGR of 14.4% in the forecast period (2018-2028) It is predicted that this increase is mainly due to the adoption of ovarian cancer maintenance treatment in the United States, the United Kingdom, France, Germany, Spain, Italy and Japan In addition, the penetration of poly ADP ribose polymerase (PARP) inhibitors in first-line therapy and increased genetic marker screening are also key drivers In terms of PARP inhibitors, three drugs are expected to occupy 40% of the global market share in 2028 - $2.8 billion Immunosuppressive drugs are also expected to contribute about $1.4 billion, and five of these drugs will enter the market However, generic and bio generic drugs targeting key therapeutic drugs for ovarian cancer (such as lynparza [Lipitor] and Avastin [avidin]) are expected to have a negative impact on market growth "The dramatic growth in the ovarian cancer market is largely due to the label expansion of PARP inhibitors such as lynparza, zejula and rubrca," explained Ufuk Ezer, oncology and hematology analyst at global data Increased screening rates for genetic markers such as BRCA mutations and other homologous recombination defects (HRD) will allow for better patient segmentation and may further promote the use of PARP inhibitors " The combination of maintenance therapy and PARP inhibitors is considered to be an important step in prolonging the life of patients with ovarian cancer In 2028, PARP inhibitors will occupy more space in the first-line treatment In addition to lynparza being awarded label extension in 2018, zejula, rubraca and veliparib, a new PARP inhibitor from Alberta, will also appear in the first-line treatment In addition, the introduction of immunocheckpoint inhibitors tecentriq, dostarlimab, opdivo, imfinzi and keytruda will help to change the treatment pattern that has been stagnant for decades Although progress has been made in the treatment of newly diagnosed patients with ovarian cancer, one of the biggest unmet needs, that is, the need of relapsed platinum resistant patients for effective treatment, has not yet been addressed In addition, the need for early diagnostic biomarkers and special treatment options for rare histological subtypes of ovarian cancer has not been met, which will provide further opportunities for diagnostic companies and drug developers Origin: ovarian cancer market set to smash $6.7 billion by 2028